Codexis, Inc.

CDXS Healthcare Biotechnology

Codexis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.4 million, up 18.6% from fiscal 2024. In the quarter to June 2026, revenue fell 2.69%, EPS grew 18.8%, free cash flow grew 48.6% and total debt fell 14.1%, each against the same quarter a year earlier.

1.25 0.11 −8.09%
Market cap
$148.9M
P/E
0.0×
Fwd P/E
−6.6×
Dividend yield
—
F-score
4/9
Altman Z
−4.75
Beneish M
−3.57
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

3 4 5 5
ROE
(114.26%) (74.88%) (68.90%) (69.36%)
ROA
(47.00%) (29.63%) (24.77%) (23.79%)
ROIC
(195.29%) (218.36%) (100.87%) (151.17%)
Return on Tangible Assets
(89.16%) (52.03%) (41.34%) (50.94%)
Average Days of Receivables
52.43 52.86 35.46 34.33
Free Cash Flow per Share
(0.68) (0.27) (0.24) (0.13)
Free Cash Flow
(61.65) (23.84) (22.11) (12.16)
Other line items

Show all line items

Columns are period end dates